Adimab expands antibody research deals with Merck, Lilly
Under the revised agreement, Merck gains expanded access to Adimab’s technology for the discovery and optimization of fully human antibody candidates. Adimab will develop therapeutic antibody candidates against
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.